default author photo

Andrea Casadei Gardini

Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele

Milano

Italy

SCHOLARLY PAPERS

3

DOWNLOADS

127

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Durvalumab Plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer: A Large Real-Life Worldwide Population

Number of pages: 28 Posted: 15 May 2024
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Vita Salute San Raffaele University, Universita di Cagliari - University Hospital of Cagliari, Careggi University Hospital of Florence - Clinical Oncology Unit, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, KU Leuven, University of Pisa, IRCCS Humanitas Research Hospital, Università Campus Bio-Medico di Roma, Seoul National University - Seoul National University Bundang Hospital, Mayo Clinic, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), AUSL Romagna - Oncology Unit, Boston Consulting Group - Berlin, University of Foggia, Fondazione IRCCS Istituto Nazionale dei Tumori, CHA University - CHA Bundang Medical Center, University of Glasgow - Institute of Cancer Sciences, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Ulsan - Department of Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, Universita di Cagliari - University Hospital of Cagliari, Medical University of Vienna, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Ulm University - Ulm University Hospital, affiliation not provided to SSRN, affiliation not provided to SSRN, San Luigi Gonzaga University Hospital, The Chinese University of Hong Kong (CUHK) - Department of Clinical Oncology, affiliation not provided to SSRN, IRCCS Humanitas Research Hospital, University of Parma, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, affiliation not provided to SSRN, AOU Careggi, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, National Cancer Center Hospital East, KU Leuven, Fondazione IRCCS Istituto Nazionale dei Tumori, Istituto Clinico Humanitas, Campus Bio-Medico University, Seoul National University - Seoul National University Hospital, Mayo Clinic Hospital - Phoenix - Division of Medical Oncology, affiliation not provided to SSRN, University of Pisa - Department of Translational Research and of New Surgical and Medical Technologies, University Hospital Frankfurt, University of Foggia, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Pisa, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), IRCCS Humanitas Research Hospital and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele
Downloads 75 (837,727)

Abstract:

Loading...

cholangiocarcinoma, durvalumab, immunotherapy, real-world evidence, biliary tract cancer, advanced disease

2.

Pemigatinib-associated toxicity and its management: implications on prognosis in patients with cholangiocarcinoma treated within real-world Italian PEMIREAL and French PEMIBIL cohorts

Number of pages: 20 Posted: 17 Dec 2025
affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Hospitalier Universitaire de Toulouse, affiliation not provided to SSRN, Gustave Roussy - Drug Development Department (DITEP), University of Bordeaux - Hôpital Haut-Lévêque, affiliation not provided to SSRN, University of Montpellier - Institut régional du Cancer de Montpellier, Centre Paul Strauss, University of Claude Bernard Lyon 1 - Centre Léon Bérard, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Pisa, University of Perugia, affiliation not provided to SSRN, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Academic Hospital of Udine ASUFC - Department of Oncology, Université de Poitiers - Gastroenterology Department, affiliation not provided to SSRN, affiliation not provided to SSRN, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Milano-Bicocca - Fondazione IRCCS San Gerardo dei Tintori, affiliation not provided to SSRN, affiliation not provided to SSRN, Centre Antoine Lacassagne, affiliation not provided to SSRN, University of Lille - CHU Lille, Institut de Cancérologie de l'Ouest - Department of Medical Oncology, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Institut Mutualiste Montsouris, École Normale Supérieure - PSL Research University - Institut Curie, Centre Eugène Marquis - Medical Oncology, Université de Rennes 1 - CHU de Rennes, University of Toulouse - Hospital Rangueil, IRCCS Humanitas Research Hospital, affiliation not provided to SSRN, Centre Hospitalier Universitaire de Toulouse and affiliation not provided to SSRN
Downloads 52 (1,041,696)

Abstract:

Loading...

Drug toxicity, adverse events, Cholangiocarcinoma, biliary tract cancer, FGFR2 fusions/rearrangements, Real-world Evidence, Systemic treatment, targeted therapy

3.

Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH1-Mutated Clusters

Posted: 29 Jun 2022
Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Universita di Cagliari - University Hospital of Cagliari, Hospital Vall d’Hebron, Università Vita-Salute San Raffaele - San Raffaele Hospital, Scientific Institute for Research, Hospitalization and Healthcare (IRCCS) - IRCCS Veneto Institute of Oncology (IOV-IRCCS), Fondazione IRCCS Istituto Nazionale dei Tumori, Universita di Cagliari - University Hospital of Cagliari, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), San Bortolo Hospital - Department of Oncology, Università Vita-Salute San Raffaele - San Raffaele Hospital, Università Vita-Salute San Raffaele - San Raffaele Hospital, Hospital Vall d’Hebron, Universita di Cagliari - University Hospital of Cagliari, Fondazione IRCCS Istituto Nazionale dei Tumori, Universita di Cagliari - University Hospital of Cagliari, San Bortolo Hospital - Department of Oncology, Vall d’Hebron Institute of Oncology (VHIO), University of Padua - Department of Medicine DIMED, University of Milan - Department of Oncology and Hemato‐Oncology (DIPO), Universita di Cagliari - University Hospital of Cagliari, San Bortolo Hospital - Department of Oncology, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Università Vita-Salute San Raffaele - San Raffaele Hospital, Vita Salute San Raffaele University, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, Universita di Cagliari - University Hospital of Cagliari and Università Vita-Salute San Raffaele - IRCCS Ospedale San Raffaele

Abstract:

Loading...

cholangiocarcinoma, IDH1 mutation, genomic profiling, next-generation sequencing, clustering analysis